Simon Christopher Kerr

Broken String Biosciences Ltd. is a company located in Chesterford Research Park, UK. Broken String Biosciences aims to develop safer cell and gene therapies by assessing the stability of the genome. The British company leverages novel genomic sequencing approaches to build a technology platform that will drive the development of CRISPR cell and gene therapies. The company's primary inventor of DNA break mapping technology, Induce-seq™, is Felix Dobbs, who holds an AstraZeneca-sponsored PhD in CRISPR genome editing and genomics from Cardiff University. The company's team includes experienced professionals with expertise in molecular biology, bioinformatics, and computational biology. The company was founded by Felix Dobbs and Simon Huw Reed, with Felix Dobbs as the CEO since incorporation.

Indigix Ltd. develops a novel platform technology that engineers synthetic molecules to modify immunological responses for diseases. Its applications include, treatment of diarrhoeal diseases, inflammatory bowel disease, and wound healing. The firm also provides pre-clinical testing services. The company was founded on June 11, 2010 and is headquartered in Solihull, the United Kingdom.

Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London.

CeNeS Pharmaceuticals Plc engages in the discovery and development of drugs. The company was founded by Alan Gilbert Goodman in 1997 and is headquartered in Cambridge, the United Kingdom.